Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB by Boer, Karin et al.
Acta Neuropathol (2008) 115:683–696
DOI 10.1007/s00401-008-0354-6
123
ORIGINAL PAPER
Cellular distribution of vascular endothelial growth factor 
A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal 
cortical dysplasia type IIB
Karin Boer · Dirk Troost · Wim G. M. Spliet · 
Peter C. van Rijen · Jan A. Gorter · Eleonora Aronica 
Received: 28 November 2007 / Revised: 18 February 2008 / Accepted: 18 February 2008 / Published online: 4 March 2008
© The Author(s) 2008
Abstract Members of the vascular endothelial growth
factor (VEGF) family are key signaling proteins in the
induction and regulation of angiogenesis, both during
development and in pathological conditions. However, sig-
naling mediated through VEGF family proteins and their
receptors has recently been shown to have direct eVects on
neurons and glial cells. In the present study, we immunocy-
tochemically investigated the expression and cellular distri-
bution of VEGFA, VEGFB, and their associated receptors
(VEGFR-1 and VEGFR-2) in focal cortical dysplasia
(FCD) type IIB from patients with medically intractable
epilepsy. Histologically normal temporal cortex and perile-
sional regions displayed neuronal immunoreactivity (IR)
for VEGFA, VEGFB, and VEGF receptors (VEGFR-1 and
VEGFR-2), mainly in pyramidal neurons. Weak IR was
observed in blood vessels and there was no notable glial IR
within the grey and white matter. In all FCD specimens,
VEGFA, VEGFB, and both VEGF receptors were highly
expressed in dysplastic neurons. IR in astroglial and bal-
loon cells was observed for VEGFA and its receptors.
VEGFR-1 displayed strong endothelial staining in FCD.
Double-labeling also showed expression of VEGFA,
VEGFB and VEGFR-1 in cells of the microglia/macro-
phage lineage. The neuronal expression of both VEGFA
and VEGFB, together with their speciWc receptors in FCD,
suggests autocrine/paracrine eVects on dysplastic neurons.
These autocrine/paracrine eVects could play a role in the
development of FCD, preventing the death of abnormal
neuronal cells. In addition, the expression of VEGFA and
its receptors in glial cells within the dysplastic cortex indi-
cates that VEGF-mediated signaling could contribute to
astroglial activation and associated inXammatory reactions.
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Introduction
The vascular endothelial growth factor (VEGF) family
includes seven members which are structurally homo-
logous, but display molecular and functional diversity [58,
81]. VEGFA, the most well known member of the VEGF
family, is a crucial regulator of angiogenesis and vascular
permeability in both physiological and pathological condi-
tions such as tumor growth, chronic inXammation, and
ischemia [10, 16, 19]. In addition to the unquestioned role
in angiogenesis, it has recently been shown that VEGFA
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has direct trophic eVects on neuronal and glial cells in the
central nervous system [10, 22, 25, 53].
VEGFB is most closely related to VEGFA [46, 81]; how-
ever, the biological function of VEGFB is less well charac-
terized than the function of VEGFA. VEGFB is expressed
early during development and appears to have prominent
expression in the central nervous system [1, 36]. Addition-
ally, VEGFB has been shown to function as an angiogenic
and neuroprotective protein [29, 63, 68] and recent evidence
suggests a role for VEGFB in neurogenesis [69, 70].
The diverse functions of VEGF proteins can be
explained by their diVerential binding to signaling VEGF
receptors [VEGFRs; VEGFR-1 (Flt-1), VEGFR-2 (Flk1/
KDR), and VEGFR-3 (Flt-4) [50, 81]]. VEGFA binds to
VEGFR-1 and VEGFR-2, whereas VEGFB binds speciW-
cally to VEGFR-1 and not to VEGFR-2 [81].
The VEGF-signaling pathway, involving both neuronal
and glial cells, has been implicated in several neurological
disorders, including neurodegeneration, stroke, and cere-
bral and spinal trauma [10]. In addition, expression of
VEGFA is upregulated in neuronal and glial cells after epi-
leptic seizures in rats [13], suggesting a role for VEGFA in
seizure disorders. A recent study points to a neuroprotective
role for VEGFA following status epilepticus [45]. The rele-
vance of these Wndings in animal models to human epileptic
disorders is uncertain. Using serial analysis of gene expres-
sion (SAGE), we recently identiWed the VEGFB gene to be
upregulated in human tissue from a patient with focal corti-
cal dysplasia (FCD) and intractable epilepsy compared to
control cortex (Boer et al., unpublished observations).
Upregulation of VEGFA and its receptor has also been
recently shown in the hippocampus of cases of human tem-
poral lobe epilepsy (TLE) [56]. However, the distribution
of VEGFA, VEGFB, and VEGFRs in epilepsy-associated
human malformations of cortical development has not yet
been deWned.
In the present study, we investigated the expression of
both VEGFA and VEGFB and their receptors (VEGFR-1
and VEGFR-2) in patients with FCD, which is a develop-
mental disorder known to be a major cause of intractable
epilepsy [73]. We report the speciWc cellular distribution,
including both the neuronal and the glial components of the
dysplastic cortex, and we discuss the potential role of
VEGFA, VEGFB, and their receptors in the histogenesis
and epileptogenesis of this developmental lesion.
Materials and methods
Subjects
The cases included in this study were obtained from the
databases of the Departments of Neuropathology of the
Academic Medical Center (University of Amsterdam;
UVA) in Amsterdam and the University Medical Center in
Utrecht (UMCU). We examined surgically resected tissue
from nine patients undergoing epilepsy surgery for focal
cortical dysplasia. Informed consent was obtained for the
use of brain tissue and for access to medical records for
research purposes. The tissue was obtained and used in a
manner compliant with the Declaration of Helsinki.
The classiWcation system proposed by Palmini et al. [48]
was used for grading the degree of FCD and only patients
with FCD type IIB located in the temporal lobe were
included. The clinical characteristics derived from the
patient’s medical records are summarized in Table 1. The
predominant type of seizure pattern was that of complex
partial seizures, which were resistant to maximal doses of
antiepileptic drugs (AEDs; carbamazepine, valproic acid,
phenytoin, levetiracetam, oxcarbazepine, and clonaze-
pam). Information concerning the exact time of last seizure
occurrence prior to surgical resection was not available.
However, all the patients included in our series did not have
seizure activity in the last 24 h before surgery. The patients
underwent presurgical evaluation [74]. Intraoperative
ECoG was performed routinely in all operations for tailor-
ing of surgery and we classiWed the post-operative seizure
outcome according to Engel [17]. Follow-up period ranged
from 1 to 9 years.
Normal-appearing control cortex/white matter from tem-
poral region was obtained at autopsy from Wve adult control
patients (male/female: 2/3; mean age 42, range 17–55)
without history of neurological diseases. All autopsies were
performed within 12 h after death (post mortem delay: 11,
11.5, 9, 8.5, 6). The cause of death was represented by
acute myocardial infarction. In addition, four of the nine
FCD cases contained suYcient amount of perilesional zone
(normal-appearing cortex/white matter adjacent to the
lesion), for comparison with the autopsy specimens. This
Table 1 Summary of clinical Wndings of patients with focal cortical
dysplasia
FCD focal cortical dysplasia, CPS complex partial seizures, SGS
secondary generalized seizures
Patient/sex/
age (years)
Diagnosis Duration of 
epilepsy (years)
Seizure 
type
Engel 
class
1/M/11 FCD IIB 11 CPS I
2/M/31 FCD IIB 20 CPS I
3/F/25 FCD IIB 9 CPS I
4/F/22 FCD IIB 21 CPS/SGS I
5/M/18 FCD IIB 14 CPS I
6/M/17 FCD IIB 10 CPS I
7/F/16 FCD IIB 11 CPS I
8/M/29 FCD IIB 21 CPS I
9/M/28 FCD IIB 21 CPS IActa Neuropathol (2008) 115:683–696 685
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material represents good disease control tissue, since it is
exposed to the same seizure activity, drugs, Wxation time,
and the age and gender are also the same.
Tissue preparation
Tissue was Wxed in 10% buVered formalin and embedded
in paraYn. Two representative paraYn blocks per case
(containing the complete lesion or the largest part of the
lesion resected at surgery) were sectioned, stained, and
assessed. ParaYn-embedded tissue was sectioned at 6 m,
mounted on organosilane-coated slides (Sigma, St Louis,
MO) and used for histological and immunocytochemical
reactions as described below. Frozen tissue from control
cortex and FCD tissue, stored at ¡80°C, was used for west-
ern blot analysis.
Antibody characterization
To document the presence of a heterogeneous population of
cells, we used the following antibodies: glial Wbrillary
acidic protein (GFAP; polyclonal rabbit, DAKO, Glostrup,
Denmark; 1:4,000; monoclonal mouse, DAKO; 1:50),
vimentin (mouse clone V9, DAKO; 1:1,000), MAP2 (poly-
clonal rabbit; Chemicon; 1:500), neuronal nuclear protein
(NeuN; mouse clone MAB377, Chemicon, Temecula, CA,
USA; 1:2,000), non-phosphorylated neuroWlament
(SMI311; Sternberger monoclonals, Lutherville, MD;
1:1,000), human leukocyte antigen (HLA)-DP, -DQ, -DR
(CR3/43; monoclonal mouse, DAKO; 1:400), CD68
(mouse clone PG-M1, DAKO; 1:200) and CD31 (mouse
clone JC70A, DAKO; 1:100).
For the detection of VEGFA, VEGFB, and their recep-
tors, the following antibodies (Abs) were used: VEGFA
(G153-694, monoclonal mouse; recognizing VEGF 165
and 189 [51], Pharmingen, CA, USA; 1:100), VEGFA (A-
20, SC-152, polyclonal rabbit; raised against the N-termi-
nus of VEGFA, recognizing VEGF 121, 165 and 189,
Santa Cruz Bio., CA, USA; 1:100), VEGFB (H-70, SC-
13083, polyclonal rabbit; raised against amino acids 1–70
of human VEGFB, Santa Cruz Bio.; 1:20), Flt-1 (VEGFR-
1; C-17, SC-316, polyclonal rabbit, Santa Cruz Bio.;
1:100), Flk-1 (VEGFR-2; A-3, SC-6251, monoclonal
mouse; Santa Cruz Bio.; 1:100). To allow comparative
analysis, we used on frozen specimens of normal (n =3 )
and FCD tissue (n = 2), two additional antibodies (which
are not suitable for staining paraYn-embedded, formalin-
Wxed tissue): VEGFR-1 (clone Flt-19, 1:400; developed
against the recombinant human extracellular domain of
VEGFR-1) and VEGFR-2 (clone KDR-1, 1:400; developed
against the recombinant human extracellular domain of
VEGFR-2), kindly provided by Dr. H. A. Weich (National
Research Center for Biotechnology, Braunschweig, Germany),
and previously characterized on human tissues [49, 64, 80].
Similar immunoreactivity patterns were observed on
paraYn-embedded and frozen tissue.
The speciWcity of the antibodies used for immunocyto-
chemistry on paraYn-embedded, formalin-Wxed tissue
(VEGFA, VEGFB, VEGFR-1, VEGFR-2; Santa Cruz
Bio.), was further tested by performing western blot analy-
sis of total homogenates of human control cortex. We also
include one FCD case of which suYcient frozen material
for blot analysis was available (Fig. 1). VEGFR1 and
VEGFR-2 receptor proteins were detectable as a band of
approximately 180 and 200 kDa, respectively; VEGFB was
detectable as a band of approximately 40 kDa; VEGFA
labeled a prominent band at approximately 48 kDa and a
Fig. 1 Representative immunoblot of VEGFA, VEGFB, VEGFR-1,
and VEGFR-2 in total homogenates from control cortex and FCD
tissue. Expression of -actin (as reference protein) is shown in the
same protein extracts686 Acta Neuropathol (2008) 115:683–696
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light band at 21 kDa (reducing conditions), as recently
reported in human brain tissue (control hippocampus and
FCD; [56]). All immunoreactive bands disappeared after
preadsorption with the corresponding peptide.
For immunoblot analysis, human normal cortex (n =3 )
and FCD (n = 1) samples were homogenized in lysis buVer
containing 10 mM Tris (pH 8.0), 150 mM NaCl, 10% glyc-
erol, 1% NP-40, Na-orthevanadate (10.4 mg/ml), 5 mM
EDTA (pH 8.0), 5 mM NaF, and protease inhibitor cocktail
(Boehringer Mannheim, Germany). Protein content was
determined using the bicinchoninic acid method [65]. Non-
reducing conditions were used to improve the detection of
the VEGFA antibody, as previously reported [8]. For elec-
trophoresis, equal amounts of proteins (30 g/lane) were
separated by sodium dodecylsulfate-polyacrylamide gel
electrophoretic (SDS-PAGE) analysis in 7.5–12.5% gels.
Separated proteins were transferred to nitrocellulose paper
for 1 h and 30 min, using a semi-dry electroblotting system
(BioRad, Transblot SD, Hercules, CA, USA). Blots were
incubated overnight in TTBS (20 mM Tris , 150 mM NaCl,
0.1% Tween, pH 7.5)/5% non-fat dry milk, containing the
primary antibody (VEGFA, VEGFR-1, and VEGFR-2,
1:1,000; VEGFB, 1:200). After several washes in TTBS,
the membranes were incubated in TTBS/5% non-fat dry
milk/1% BSA, containing the goat anti-rabbit coupled to
horseradish peroxidase (1:2,500; Dako, Denmark) for 1 h.
After washes in TTBS, immunoreactivity was visualized
using an enhanced chemiluminescence kit (Amersham,
Buckinghamshire, UK). Expression of -actin (monoclonal
mouse, Sigma, St Louis, MO; 1:50,000) was used as refer-
ence protein. Because of the limited availability of frozen
material from FCD cases, a complete analysis with statisti-
cal comparison between control and FCD by immunoblot
could not be performed.
Immunocytochemistry
Sections were deparaVinized, re-hydrated, and incubated
for 20 min in 0.3% H2O2 diluted in methanol to quench the
endogenous peroxidase activity. Antigen retrieval was per-
formed by incubation for 10 min at 121°C in citrate buVer
(0.01 M, pH 6.0); sections were washed with phosphate-
buVered saline (PBS), and incubated for 30 min in 10%
normal goat serum (Harlan Sera-Lab, Loughborough,
Leicestershire, UK). We incubated the sections with the
primary antibodies overnight at 4°C. Hereafter, sections
were washed in PBS and we used the ready-for-use Power-
vision peroxidase system (Immunologic, Duiven, The
Netherlands) and 3,3-diaminobenzidine as chromogen to
develop the staining. Sections were counterstained with
hematoxylin, dehydrated, and coverslipped. Sections incu-
bated without the primary antibody and excess of the anti-
genic peptide were essentially blank.
For double-labeling studies, after incubation overnight at
4°C with the primary antibodies, sections were incubated
for 2 h at RT with Alexa Fluor® 568-conjugated anti-rabbit
IgG and Alexa Fluor® 488 anti-mouse IgG (1:1,000;
Molecular Probes, The Netherlands). The VEGFR-2 anti-
body (monoclonal mouse) could only be combined with
MAP2 and GFAP (polyclonal rabbit). Sections were ana-
lyzed by means of a laser scanning confocal microscope
(Bio-Rad, Hercules, CA, USA; MRC1024) equipped with
an argon-ion laser.
Evaluation of immunostaining
Semi-quantitative evaluation of immunoreactivity
As previously reported [3, 54], a semi-quantitative analysis
was done using an Olympus microscope and examining in
each section, high-power non overlapping Welds (of
0.0655 £ 0.0655 mm width, each corresponding to
4.290 m2), deWned in the center of the lesion using a
square grid inserted into the eyepiece. A total microscopical
area of 858.050 m2 was assessed per case. Neuronal cell
bodies were diVerentiated from glia and glia-neuronal bal-
loon cells on the basis of morphology. Balloon cells have
eccentric nuclei and ballooned opalescent eosinophilic
cytoplasm. The staining intensity was evaluated using a
semi-quantitative three-point scale where immunoreactivity
was deWned as: ¡ absent (0); + moderate (1); ++ strong
staining (2); intensity score (Table 2). This score represents
the predominant cell staining intensity found in each
section for the diVerent cell types (neurons, astrocytes,
microglial cells, and balloon cells) as averaged from the
selected Welds (as previously described [3, 54]).
Frequency of cell staining
In each slice, we assessed the number of neurons and astro-
cytes labeled by a speciWc Ab on the total number of each
Table 2 VEGFA, VEGFB, VEGFR-1, and VEGFR-2 distribution in
diVerent cellular types in cases of FCD (% of cases with immuno-
reactive cells)
FCD focal cortical dysplasia; immunoreactivity: ¡ not present,
+ moderate, ++ strong
Focal cortical dysplasia (n =9 )
Neurons Astrocytes Balloon cells
¡ ++ + ¡ ++ + ¡ ++ +
VEGFA 0 22% 78% 0 11% 89% 0 11% 89%
VEGFB 0 33% 67% 78% 22% 0 78% 22% 0
VEGFR-1 0 55% 45% 0 22% 78% 0 33% 67%
VEGFR-2 0 11% 89% 55% 45% 0 22% 45% 33%Acta Neuropathol (2008) 115:683–696 687
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cell type within the lesion using an ocular grid [4]. This fre-
quency score was assigned using three distinct categories:
(1) <10%, rare; (2) 11–30%, sparse; (3) >30%, high. The
product of the intensity and the frequency scores was taken
to give the total immunoreactivity score, as previously
reported [23, 54].
For statistical analysis of data, SPSS for Windows was
used. Data were compared using a non-parametric Kruskal–
Wallis test followed by a Mann–Whitney test to assess the
diVerence between groups. P < 0.05 was taken as the level
of signiWcance.
Results
Human material and histological features
All nine patients had chronic pharmacoresistant epilepsy
and were all seizure-free postoperatively (Engel’s class I;
Table 1). The FCD cases included in this study have all the
histopathological features of severe (type IIB) FCD,
according to the classiWcation of Palmini et al. [48]. The
resected specimens consisted of disorganized neocortex
containing immature neurons, giant neurons, dysmorphic
neurons, and balloon cells. Neurons and balloon cells were
also observed in the subcortical white matter and there was
a prominent population of reactive astrocytes. Cells of the
microglia/macrophage lineage were also observed within
the dysplastic cortex, suggesting activation of inXammatory
processes in FCD [6].
Expression of VEGF and VEGFR in normal temporal 
cortex and FCD
Cellular distribution of VEGFA
VEGFA staining was observed within the histologically
normal cortex (Fig. 2a, b). The staining was strongest in
pyramidal neurons, which displayed somatic staining and
staining of the apical dendrites (Fig. 2b). Neuropil staining
was weak and resting glial cells did not show VEGFA
immunoreactivity (IR). Weak staining was observed in
endothelial cells. Autopsy material and the perilesional cor-
tex showed similar IR.
In the majority of FCD cases, strong VEGFA immunore-
activity (IR) was observed in dysplastic neurons located
throughout the dysplastic cortex (Fig. 2c–e; Table 2;
Fig. 6). Strong staining was also detected in balloon cells,
reactive astrocytes, and in perivascular astrocytic end-feet
(Fig. 2f–i; Table 2; Fig. 6). Endothelial IR was weak. Dou-
ble-labeling experiments conWrmed expression in reactive
astrocytes, neurons, and in CD68+ macrophages (Fig. 2p).
Immunocytochemistry using two diVerent antibodies to
VEGF (Pharmingen and Santa Cruz Bio.) demonstrated
similar patterns.
Cellular distribution of VEGFB
Histologically normal cortex displayed only weak VEGFB
IR (Fig. 3a). Both autopsy and surgical specimens showed
light staining in pyramidal neurons and in endothelial cells.
Glial cells did not show VEGFB IR.
In FCD specimens, moderate to strong VEGFB IR was
observed within the dysplastic cortex (Fig. 3b; Table 2;
Fig. 6) with strong VEGFB IR in dysplastic neurons
(Fig. 3c). In the majority of cases (seven out of nine),
balloon cells and reactive astrocytes did not express
VEGFB (Fig. 3d; Table 2; Fig. 6). Double-labeling
experiments conWrmed the absence of VEGFB IR in
GFAP-positive cells (astrocytes), whereas co-localiza-
tion was found with neuroWlament in dysplastic neurons
(Fig. 3h–j). VEGFB IR was also observed in CD68+
macrophages (Fig. 3k).
Cellular distribution of VEGFR-1
Histologically normal cortex (autopsy and surgical speci-
mens) displayed only weak VEGFR-1 IR, which was
restricted to pyramidal neurons (Fig. 4a). IR in blood ves-
sels was weak (Fig. 4b). Glial cells did not show VEGFR-1
IR.
In FCD specimens, moderate to strong VEGFR-1 stain-
ing was observed within the dysplastic cortex (Fig. 4c–g;
Table 2; Fig. 6). VEGFR-1 IR was observed in diVerent
cell types, including dysplastic neurons, astrocytes, and
endothelial cells. Double-labeling experiments conWrmed
the co-localization of VEGFR-1 IR with neuronal (inset in
Fig. 4c), endothelial (inset in Fig. 4d), and glial (Fig. 4h–j)
markers. Additionally, expression of VEGFR-1 was
observed in CD68+ macrophages (Fig. 4k–m).
Cellular distribution of VEGFR-2
VEGFR-2 staining was observed within the histologically
normal cortex (autopsy and perilesional zone) in pyramidal
neurons (Fig. 5a). IR in blood vessels was weak (Fig. 5b).
Glial cells did not show VEGFB IR.
In the large majority of FCD cases (eight out of nine),
VEGFR-2 was strongly expressed in dysplastic neurons
(Fig. 5c, e; Table 2; Fig. 6). VEGFR-2 IR was also detected
in balloon cells, but only three out of nine cases displayed
strong staining for VEGFR-2 (Fig. 5f; Table 2). Endothelial
expression was weak. In many FCD cases (Wve out of nine),
expression of VEGFR-2 was undetectable in reactive astro-
cytes (Table 2). Double-labeling experiments conWrmed the
co-localization of VEGFR-2 IR with neuronal markers688 Acta Neuropathol (2008) 115:683–696
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Fig. 2 VEGFA immunoreactivity in focal cortical dysplasia type IIB.
a VEGFA immunoreactivity (IR) within the histologically normal
adult cortex. b High magniWcation showing somatic staining in pyra-
midal neurons (inset: vascular staining). c VEGFA in focal cortical
dysplasia (FCD; type IIB) showing strong IR within the dysplastic cor-
tex. d High magniWcation showing VEGFA IR in dysplastic neurons
(arrows). e A binucleated VEGFA positive dysplastic neuron. f VEG-
FA IR within the subcortical dysplastic region. g VEGFA expression
in a balloon cell. h, i VEGFA expression in reactive astrocytes (arrows
in i indicate perivascular astrocytic end-feet) j–l double-labeling of
GFAP (green, j) with VEGFA (red, k) shows co-localization (yellow,
l) in astrocytes. m–o Double-labeling of non-phosphorylated neuroWl-
ament (SMI311; NF, green, m) with VEGFA (red, n) shows co-local-
ization (yellow, o) in dysplastic neurons. p Merged image showing
co-localization of CD68 (green) with VEGFA (red) in macrophages.
Scale bar in a a, c, f 400 m; b, d 120 m; e, g–i 35 m; j–o 40 m;
p 18 mActa Neuropathol (2008) 115:683–696 689
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(neuroWlament or MAP2, Fig. 5e, g–i) within the dysplastic
cortex.
Discussion
In addition to their role in angiogenesis, VEGF proteins and
their receptors have been implicated in several neurological
disorders, including epilepsy [13, 44, 56]. In the present
study, we demonstrate a prominent expression of VEGFA,
VEGFB, and their signaling receptors in FCD type IIB, a
malformation of cortical development associated with
intractable epilepsy. This is particularly interesting in view
of the recently proposed role of VEGFs and their signaling
pathways during development and in epilepsy-associated
pathologies [13, 26, 33, 69, 76].
Expression of VEGFA and VEGFB in normal temporal 
cortex
In histologically normal temporal cortex (autopsy and
perilesional zone), we have shown weak expression of
both VEGFA and VEGFB in cortical neurons. Expres-
sion of VEGFA and VEGFB, including both mRNA and
protein, has been demonstrated in neurons in adult
rodent brain [39, 41, 42, 72]. In human adult brain, only
few studies have described neuronal expression of
VEGFA in control tissue [8, 78], which was similar to
Fig. 3 VEGFB immunoreactiv-
ity in focal cortical dysplasia 
type IIB. a Histologically nor-
mal adult cortex, showing neuro-
nal distribution of VEGFB with 
weak immunoreactivity (IR) in 
pyramidal cell neurons (high 
magniWcation of a pyramidal 
neuron is shown in the inset aI); 
weak staining was also observed 
in blood vessels (inset aII). b 
VEGFB in focal cortical dyspla-
sia (FCD; type IIB) showing 
strong IR within the dysplastic 
cortex. c Strong VEGFB IR in 
dysplastic neurons of diVerent 
size and shape (arrows). d 
Undetectable VEGFB IR in bal-
loon cells (arrows). e–g Absence 
of co-localization between 
GFAP (green, e) with VEGFB 
(red, f) in astrocytes (g, merged 
image). h–j Double-labeling of 
non-phosphorylated neuroWla-
ment (SMI311; NF, green, h) 
with VEGFB (red, i) shows co-
localization (yellow, j) in dys-
plastic neurons. k Merged image 
showing co-localization of 
CD68 (CD68; green) with VEG-
FB (red) in macrophages. Scale 
bar in a a, b 200 m; c–j 40 m; 
k 18 m690 Acta Neuropathol (2008) 115:683–696
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our observed staining pattern in the control temporal
specimens.
To our knowledge, previous studies of VEGFB protein
expression in human control cortex have not been
described. However, VEGFB mRNA was detected in
human hippocampal cortex [24], and VEGFB mRNA and
protein expression has been described in adult rodent brain
[36, 42]. In control rat brain, VEGFB was constitutively
expressed in endothelial cells [42]. In our study, we
observed only weak endothelial VEGFB IR in blood ves-
sels. In agreement with previous studies [8, 36, 78], immu-
noreactivity (IR) for both VEGFs was not observed in glial
cells within control specimens.
DiVerential cellular distribution of VEGFA and VEGFB 
in FCD
In the present study, we provide evidence for a consistent
expression of both VEGFA and VEGFB within the dys-
plastic cortex of patients with FCD. Both VEGFs are highly
expressed in dysplastic neurons; however, only the VEGFA
protein is prominently expressed in reactive astrocytes.
Expression of VEGFA in astrocytes has been shown in sev-
eral other pathologies associated with reactive gliosis, such
as ischemic stroke, traumatic brain injury, neurodegenera-
tive disorders, and the hippocampus following entorhinal
deaVerentation [8, 27, 59, 78, 79]. In addition, we previously
Fig. 4 VEGFR-1 immunoreac-
tivity in focal cortical dysplasia 
type IIB. a, b Histologically nor-
mal adult cortex (a) and white 
matter (b) showing weak immu-
noreactivity (IR) in neurons (a) 
and blood vessels (b; arrow-
heads). c, d VEGFR-1 in focal 
cortical dysplasia (FCD; type 
IIB) showing strong IR in dys-
plastic neurons (c; arrows) and 
in blood vessels (d; arrows). In-
set in c Co-localization between 
non-phosphorylated neuroWla-
ment (SMI311; NF, green) with 
VEGFR-1 (red) in dysplastic 
neurons. Inset in d Co-localiza-
tion between CD31 (endothelial 
marker; green) with VEGFR-1 
(red) in blood vessels. e–g 
Strong IR in balloon cells of 
diVerent size (arrows) and glial 
cells (arrowheads in e). h–j Co-
localization between GFAP 
(green, h) with VEGFR-1 (red, 
i) in astrocytes (j, merged im-
age). k–m Co-localization of 
CD68 (CD68; green, k) with 
VEGFR-1 (red, l) in macro-
phages (m, merged image). 
Scale bar in a a–d and h–m 
40 m; e–g 35 mActa Neuropathol (2008) 115:683–696 691
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reported upregulation of both neuronal and glial VEGFA
expression in patients with hemimegalenchephaly, an epi-
lepsy-associated malformation of cortical development [5,
7]. In the present study, we also observed expression of
VEGFA in balloon cells, which are characteristic cell types
of severe FCD [48]. Whether these cells are glial or neuro-
nal in nature is still controversial [12].
Induction of both neuronal and astroglial VEGFA expres-
sion has been shown in diVerent experimental models of sei-
zures and human temporal lobe epilepsy (TLE) [13, 44, 56].
Rigau et al. [56] showed increased levels of VEGFA in the
hippocampus of several cases of TLE, including two cases
of focal dysplasia. All TLE cases showed VEGFA expres-
sion in pyramidal neurons and granule cells of the hippo-
campus [56]. However, immunocytochemical analysis of the
temporal cortex and the FCD cases was not performed.
The molecular mechanism underlying the induction of
VEGFA expression after seizures remains unclear. One
possible mechanism, which has been proposed to explain
the association between seizure activity and the induction
of VEGFA expression, is represented by the stabilization of
the hypoxia inducible factor-1 (HIF-1). HIF-1 is a tran-
scription factor which upregulates VEGFA transcription
under hypoxic conditions [21, 38, 61]. Hypoxia may occur
during seizures, representing an important trigger in the
induction of VEGFA expression, particularly in case of
long lasting seizures, such as in status epilepticus models.
However, VEGFA expression is already induced after acute
seizures [44] and the mechanisms that regulate VEGFA
expression are complex. Several transcription factors,
including AP-1, HIF-1, and NF-B, have been identiWed
to regulate VEGFA expression [31], and recently it has also
been shown that inXammatory cytokines, such as interleu-
kin-1 (IL-1), activate HIF1 and VEGFA gene expres-
sion in primary human astrocytes [2]. Interestingly,
increased expression of proinXammatory cytokines and
related molecules has been reported in both animal models
and human epilepsy-associated pathologies, including FCD
[3, 15, 54, 77]. In addition, VEGFA has been demonstrated
to be a key mediator of the inXammatory process [14, 35].
Thus, we might speculate that the prominent expression of
VEGFA within the dysplastic cortex could be a critical
component of the complex cascade of events leading to a
chronic inXammatory state and the sustained seizure activity
Fig. 5 VEGFR-2 immunoreac-
tivity in focal cortical dysplasia 
type IIB. a, b Histologically nor-
mal adult cortex (a) and white 
matter (b) showing moderate 
immunoreactivity (IR) in pyra-
midal cells (a); in the white mat-
ter, endothelial IR was weak and 
glial IR was under detection lev-
el (b). c, d VEGFR-2 in focal 
cortical dysplasia (FCD; type 
IIB) showing strong IR in dys-
plastic neurons (arrows in c), but 
weak IR in blood vessels 
(arrowheads in d). e, f Strong IR 
in a dysplastic neuron (arrow in 
e) and in a balloon cell (arrow in 
f), but weak IR in glial cells 
(arrowheads in e, f). Inset in e 
Co-localization between non-
phosphorylated neuroWlament 
(SMI311; NF, green) with VEG-
FR-2 (red) in a dysplastic neu-
ron. g–i Co-localization between 
MAP-2 (green, g) with VEGFR-
2 (red, h) in balloon cells (i, 
merged image). Scale bar in a 
a–d and g–i 40 m; e, f 35 m692 Acta Neuropathol (2008) 115:683–696
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[76, 77]. With respect to inXammation, inXammatory cells,
such as macrophages, can also release various angiogenic
cytokines including VEGFs [71]. Accordingly, we
observed expression of both VEGFA and VEGFB in mac-
rophages (CD68-positive cells), as previously shown in ani-
mal models of brain ischemia [11, 42, 52].
VEGFA eVects can also compromise the integrity of the
blood–brain barrier (BBB; [60]). Interestingly, alterations
of the BBB permeability have been recently observed in
both human and experimental temporal lobe epilepsy with
positive correlation between the increased vascular perme-
ability and the occurrence of spontaneous seizures in
chronic epileptic rats [55, 56, 75].
In contrast, several studies highlight a dichotomous
function of VEGFA, also demonstrating a neuroprotective
role [13,  47]. Administration of VEGFA and neuronal
expression of VEGFA have been shown to stimulate neuro-
genesis in vitro and in vivo [9, 28]. In addition, it has been
suggested that the neuroprotective eVects of VEGFA are
mediated by the neuronal VEGFR-2 and the subsequent
activation of the PI3K/Akt survival pathway [32, 67].
VEGFB expression is not induced by hypoxia or several
transcription factors known to regulate VEGFA expression
[18], as the promoter region of VEGFB lacks HIF-1 and AP-
1 sites [43, 62]. The regulation of the expression of VEGFB
remains unknown. Since all cases examined were associated
with epilepsy, we cannot exclude that chronic seizure activ-
ity could also contribute to the VEGFB expression in FCD
specimens. Alternatively, since VEGFB expression has been
shown to be prominent during early brain development [36],
the strong neuronal expression of VEGFB could represent
an intrinsic and immature feature of the dysplastic neuronal
cells that could contribute to their survival. Recent studies
using VEGFB knock-out mice demonstrate a neurotrophic
and neuroprotective activity of VEGFB, exerting a direct
action on neurons, and promoting neurogenesis [68, 69].
This is an observational study and we were, therefore,
not able to investigate the spatio-temporal regulation of the
VEGF system. Further research in animal models of corti-
cal dysplasia is clearly needed to elucidate the role of
VEGFs and their signaling pathways in the histogenesis or
epileptogenesis of developmental disorders.
Fig. 6 Distribution of immuno-
reactivity scores (total score; see 
details in “Materials and meth-
ods” section) in neurons and 
astrocytes of control, perilesion-
al, and FCD specimens. a, e 
VEGFA; b, f VEGFB; c, g 
VEGFR-1; d, h VEGFR-2. a–d 
Neurons; e–h astrocytes. IR 
scores of VEGFs and VEGFRs 
in neurons of FCD were greater 
than IR scores of VEGFs and 
VEGFRs of control and perile-
sional cortex; scores of VEGFA 
and VEGFRs in astrocytes of 
FCD were greater than IR scores 
of VEGFA and VEGFRs of con-
trol and perilesional cortex 
(P < 0.05). There were no sig-
niWcant diVerences in IR scores 
of VEGFs and VEGFRs be-
tween control and perilesional 
cortex
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Expression of VEGF receptors in normal temporal cortex
In histologically normal temporal cortex (autopsy and per-
ilesional zone), VEGFR-1 and VEGFR-2 showed a similar
pattern of expression, with weak to moderate immunostain-
ing in pyramidal neurons. Neuronal expression of VEG-
FRs’ mRNA and protein has been reported in adult human
and rodent brain, with strong expression in the hippocam-
pus [8, 11, 78, 79]. In agreement with these studies, we did
not detect glial VEGFR expression in histologically normal
cortex and only weak VEGFR expression was observed in
endothelial cells.
DiVerential cellular distribution of VEGFR-1 
and VEGFR-2 in FCD
Consistent expression of both VEGFR-1 and VEGFR-2
was detected within the dysplastic cortex of patients with
FCD. Both receptors were upregulated in dysplastic neu-
rons. Increased expression of the VEGFRs and, in particu-
lar VEGFR-1, was observed in reactive astrocytes.
Upregulation of VEGFRs in neurons and reactive astro-
cytes has been shown in several other pathological condi-
tions including ischemia, neurodegenerative diseases, and
trauma [8, 11, 37, 39, 66, 79]. Recently, increased expres-
sion of VEGFR-2 has been shown in several cases of
TLE, including two cases of cortical dysplasia [56].
Immunocytochemical analysis demonstrated expression
only in endothelial cells, whereas neuronal VEGFR-2 IR
was not detected in either control hippocampus or TLE
specimens [56]. DiVerences in the phenotypes of cells
expressing VEGFRs have been observed in several other
studies [8, 30, 52]. These discrepancies may be caused by
diVerences in experimental methods, tissue processing, or
the use of diVerent antibodies that recognize diVerent
epitopes.
Our results support the neuronal expression of VEGFR-2
recently reported in human brain [8]. The similar expres-
sion pattern of VEGFA and VEGFR-2, with prominent
neuronal IR, suggests autocrine/paracrine eVects on dys-
plastic neurons, supporting the hypothesis of a mechanism
to protect abnormal neurons from cell death associated with
seizures. Autocrine and/or paracrine eVects of VEGFA are
supported by the observation that administration of
VEGFA has been shown to induce mRNA and protein
expression of both receptors in adult rat brain [34, 57]. A
protective mechanism of VEGFA has been suggested in
epileptic rats, showing that VEGFA may reduce spontane-
ous discharges in epileptic rats [40]. Therefore, upregula-
tion of VEGFA could represent an endogenous
compensatory mechanism to reduce excitability and to pre-
vent cell loss after severe seizures. Accordingly, infusion of
VEGFA into the hippocampus has been shown to protect
against neuronal cell loss after pilocarpine-induced status
epilepticus [45].
In the present study, we also provide evidence for the
expression of VEGFR-1 in activated cells of the microglia/
macrophage lineage, which have been shown to be present
in FCD specimens [6]. This is in agreement with previous
in vitro and in vivo studies [11, 20] showing VEGFR-1
expression in activated microglial cells. These observations
suggest that the microglia/macrophage lineage is also a tar-
get for VEGF, which may aVect chemotaxis and prolifera-
tion of these cells, contributing to the inXammatory state in
the epileptic brain.
There is substantial information about the function and
the signaling through VEGFR-2; in contrast, signaling
through VEGFR-1 remains poorly understood and has been
a matter of discussion. A decoy role has been proposed for
VEGFR-1, but more recently, functional signaling via
VEGFR-1 has been reported (for reviews see [43,  67]).
These observations may give rise to new therapeutic strate-
gies focusing on VEGFR-1 speciWc ligands, such as
VEGFB [43].
Although a rapid induction of VEGF and its receptors
has been shown in diVerent experimental models of sei-
zures [13,  44,  56], seizures alone cannot account for
changes in neuronal and glial expression in FCD since per-
ilesional tissue was exposed to seizures but did not show
signiWcant upregulation of VEGFs and/or VEGFRs. There-
fore, the lesion per se or the concomitant presence of the
lesion and the epileptic activity, are likely to play a role in
modulating the VEGF system in these developmental disor-
ders.
Conclusions
Our observed cellular distribution of VEGFA, VEGFB, and
their signaling receptors indicate that diVerent cellular com-
ponents of FCD are involved in VEGF-signaling. In this
context, future studies, using both in vivo and in vitro mod-
els, will be important to achieve a better understanding of
the role of the VEGF-mediated pathways in the histogene-
sis and epileptogenesis of developmental lesions associated
with intractable chronic epilepsy. Presently, signaling via
VEGF receptors is not targeted by existing therapies in epi-
leptic patients, but it can be potentially useful in view of its
involvement in the regulation of neurogenesis, inXamma-
tion, and BBB integrity. However, an eVective therapeutic
intervention based on modulation of the VEGF system has
to take into consideration the speciWc role of VEGFA and
VEGFB and the multiple eVects (protective and/or detri-
mental) reported for VEGFA.694 Acta Neuropathol (2008) 115:683–696
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